According to a prepared statement, Timothy Garnett, chief medical official at Eli Lilly said:
“While there were no new safety findings, the study failed to demonstrate that Xigris improved patient survival and thus calls into question the benefit-risk profile of Xigris and its continued use,” Timothy Garnett, Lilly’s chief medical officer, said in a prepared statement. “Patients currently receiving treatment with Xigris should have treatment discontinued, and Xigris treatment should not be initiated for new patients.”
In a prepared statement on the European Medicines Agency website, the site stated:
“These results call into question the overall benefit-risk balance of Xigris for the indicated patient population (severe sepsis). Eli Lilly has thus decided to withdraw the product from the market worldwide.”
Image via Flickr user emagineart
To learn more about Xigris, visit the official website here.